

Mannogem® XL Mannitol USP/EP/JP

Superior Tableability

Mannogem XL is an innovation in directly compressible spray-dried mannitol. XL is designed to deliver a higher level of performance during formulation, manufacture, and patient use; simply a step-change in DC mannitol performance.

Introduction

Tabletability can be defined as the ability of a powder to form a tablet of adequate strength when force is applied to that powder¹ and is generally assessed by means of testing the resultant tablet hardness, tensile strength, and friability. For conventional swallow tablets, a tensile strength of > 1.7MPa² is generally seen as the minimum requirement to show adequate tablet robustness.

Background

Studies were undertaken comparing the tabletability of Mannogem XL to a standard spray dried mannitol competitor product. Tablets were formulated with non-direct compressible APAP chosen as a difficult-to-tablet model compound and compressed using 0.551" FFBE tooling to a tablet weight of 500 mg. Samples were taken at the various compression forces and tested to evaluate tensile strength and friability. The data are presented in Figures 1 and 2 below.




Figure 1: Tablet tensile strength (MPa) versus compression force (kN) for Mannogem XL and a competitor spray dried mannitol at 15% drug loading.




Figure 2: Tablet friability (%) versus tablet hardness (kPa) for Mannogem XL and a competitor spray dried mannitol at 15% drug loading.

Results

Data show a 25% increase in the tabletability of the formulation when using Mannogem XL at 15% drug loading. A completely linear profile for tensile strength versus compression force indicates a robust formulation that is not prone to tablet problems such as capping.

Tablet robustness is a key Critical Quality Attribute for any formulation and is assessed in terms of both tensile strength as above but also in terms of friability. An ideal formulation will have a requisite high tensile strength and associated low friability at a range of compression forces. Formulations based on Mannogem XL achieve the requisite target for swallow tablets of 1.7MPa TS at lower compression forces than for other mannitols and retain low friability. Data in Figure 2 show good friability over a range of tablet hardness when using XL vs competitive product. Such formulations can be considered robust and therefore less prone to scale-up issues or failures during manufacture.

Mannogem XL has superior tabletability to other conventional spray dried mannitols, leading to the possibility of higher drug loadings in more robust tablets. This has multiple benefits:	
Patients	
Smaller, less friable tablets	
Formulators	
Simpler and quicker development that is less prone to scale up issues	
Manufacturers	
Faster speeds, at lower compression forces and less failures improve productivity, cost efficiency, and reduced tooling wear and tear	

References

1. Compression behaviour of orthorhombic paracetamol. Etienne Joris, Piera Di Martino, Christophe Berneron, Anne-Marie Guyot-Hermann and Jean Claude Guyot. Pharm Research Vol 15 No. 7 1998.
2. Developing Solid Oral Dosage Forms 2nd Edition, Pharmaceutical Theory and Practice, p905 Edited by Qiu Y, Chen Y, Zhang G, Yu L and Mantri R.U 2017. Carino, G. and Mathiowitz, E. Oral insulin delivery, Adv. Drug Del. Rev. 35, 249-257 (1999).

OUR PRODUCTS AND SERVICES CAN HELP YOU TO SOLVE THE MOST CHALLENGING FORMULATION PROBLEMS— EFFICIENTLY, COST-EFFECTIVELY AND WITH A FOCUS ON SERVICE.

ANTACID ACTIVES

The global leader in immediate-relief antacid actives, we specialize in aluminum, magnesium, calcium products, and preformulated solutions for the production of antacid suspensions and tablets.

DRUG DELIVERY SYSTEMS

A full spectrum of ODT products, services, and technologies to support every stage of your product life cycle.

TASTE-MASKED ACTIVES

Our Actimask® technology provides an excellent taste barrier and mouthfeel without hindering API release and onset of therapeutic relief.

FUNCTIONAL EXCIPIENTS

Ingredients and formulation expertise to support a wide range of patient friendly dosage forms.

VACCINE ADJUVANTS

Years of expertise in aluminum hydroxide chemistry ensure our vaccine adjuvants exhibit a very regular profile in terms of compliance, morphology, particle size distribution, and protein adsorption capacity.

DRUG DEVELOPMENT SERVICES

Our complete drug development and testing service can provide unique options to energize your drug portfolio. No time? Limited resources? We can deliver your project to you.

 SPI Pharma

 @spipharma

 salesinfo@spipharma.com

 www.spipharma.com

 @spipharma_real

 SPI Pharma



All information and statements given in this brochure are believed to be accurate at the time of publication. However, neither SPI Pharma nor any of their affiliates make any representations or warranty with respect thereto, including, but not limit to, any results obtained in the processing of the products by customers or any third party. All information and statements are intended for persons having the required skill and know-how and do not relieve the customer or user from verifying the suitability of information and statements given for a specific purpose prior to use of products. It is entirely the obligation of the customer or user to comply with applicable laws and regulations, and also with all patent or other intellectual property rights of third parties.

SPI PHARMA EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, AS TO THE ACCURACY, CURRENCY, COMPLETENESS AND/OR THE MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY INFORMATION CONTAINED IN THIS BROCHURE AND/OR ANY PRODUCT DESCRIBED OR PROMOTED IN THIS BROCHURE, INCLUDING WARRANTIES WITH RESPECT TO INFRINGEMENT OF ANY PATENT, COPYRIGHT, OR OTHER RIGHTS OF A THIRD PARTY. We reserve the right to change product specification and not specified properties of the products without prior notice.